8-K: AbbVie Updates 2024 Earnings Guidance, Cites $82 Million Impact from Acquired IPR&D in Q3

AbbVie has revised its 2024 earnings guidance to include an $82 million expense related to acquired IPR&D and milestones in the third quarter, impacting both GAAP and adjusted non-GAAP diluted earnings per share by $0.04.

Summary

• AbbVie has released an update to its financial guidance for 2024, specifically addressing the impact of acquired In-Process Research and Development (IPR&D) and milestone expenses.
• The company expects to incur $82 million in pre-tax expenses related to acquired IPR&D and milestones in the third quarter of 2024.
• This expense will negatively impact both GAAP and adjusted non-GAAP diluted earnings per share by $0.04.
• The updated full-year 2024 adjusted diluted earnings per share guidance range is now $10.67 to $10.87, which includes the $82 million expense.
• The third quarter 2024 adjusted diluted earnings per share guidance range is $2.88 to $2.92, also reflecting the $82 million expense.
• AbbVie does not forecast acquired IPR&D and milestone expenses beyond the third quarter due to the uncertainty of these transactions.

Sentiment

Score: 4

Explanation: The document conveys a negative sentiment due to the downward revision of earnings guidance caused by the IPR&D expense. While the company is transparent about the impact, the reduction in EPS is unfavorable for investors.

Negatives

• The $82 million expense for acquired IPR&D and milestones will negatively impact both GAAP and adjusted non-GAAP diluted earnings per share by $0.04.
• The full-year and third quarter adjusted diluted EPS guidance ranges have been lowered to reflect this expense.

Risks

• The final results for the quarter ended September 30, 2024, are subject to financial statement closing procedures and may differ from these preliminary estimates.
• Future acquired IPR&D and milestone expenses are difficult to predict, which could impact future earnings.
• The company faces risks related to intellectual property, competition, research and development, litigation, and regulatory changes.

Future Outlook

AbbVie's 2024 adjusted diluted EPS guidance excludes any impact from acquired IPR&D and milestones expense that may be incurred beyond the third quarter of 2024, as both cannot be reliably forecasted.

Management Comments

• AbbVie does not forecast acquired IPR&D and milestones expense due to uncertainty of the future occurrence and timing of these transactions.
• AbbVie undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

Industry Context

The pharmaceutical industry often sees fluctuations in earnings due to R&D expenses and acquisitions, making AbbVie's update a typical event in the sector. The unpredictability of IPR&D expenses is a common challenge for companies in this space.

Comparison to Industry Standards

• Other large pharmaceutical companies like Pfizer, Merck, and Johnson & Johnson also experience fluctuations in earnings due to R&D and acquisition costs.
• The $82 million IPR&D expense is not unusual for a company of AbbVie's size, but the impact on EPS is a key metric for investors.
• Companies in the pharmaceutical sector often provide adjusted EPS guidance to account for non-recurring items like IPR&D expenses, which is a standard practice.

Stakeholder Impact

• Shareholders will see a reduction in earnings per share due to the IPR&D expense.
• Analysts and investors will need to adjust their models to reflect the updated guidance.
• The company's financial performance may be viewed less favorably in the short term.

Next Steps

• AbbVie will finalize its financial results for the quarter ended September 30, 2024.
• The company will continue to monitor and report on any significant changes in its financial outlook.

Key Dates

Keywords

AbbVie, Earnings Guidance, IPR&D, Milestones, Adjusted EPS, Financial Results, Pharmaceuticals, Acquisition, Research and Development